Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de ago de 2006
ID: NCT00363415
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
INTERVENTIONAL
Inicio: 30 de oct de 2023
ID: NCT05943535
Completado
Fase 4
ClinicalTrials.gov
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
INTERVENTIONAL
Inicio: 10 de ago de 2020
ID: NCT04502862
Completado
Fase 2
ClinicalTrials.gov
A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma
INTERVENTIONAL
Inicio: 1 de ago de 2011
ID: NCT01402986
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
INTERVENTIONAL
Inicio: 3 de abr de 2024
ID: NCT06312137
Completado
Fase 4
ClinicalTrials.gov
Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia
INTERVENTIONAL
Inicio: 21 de abr de 2020
ID: NCT04355637
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)
INTERVENTIONAL
Inicio: 22 de abr de 2022
ID: NCT05274750
Reclutando
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations
INTERVENTIONAL
Inicio: 30 de oct de 2024
ID: NCT06644768
Reclutando
ClinicalTrials.gov
Incidence of Complications From the Alveolar Opening Maneuver in Mechanically Ventilated Children With Respiratory Distress Syndrome
OBSERVATIONAL
Inicio: 18 de ago de 2025
ID: NCT07233304
Reclutando
ClinicalTrials.gov
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
OBSERVATIONAL
Inicio: 20 de dic de 2025
ID: NCT06717295
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
INTERVENTIONAL
Inicio: 15 de abr de 2019
ID: NCT03930732
Completado
ClinicalTrials.gov
Study of Cases and Controls on Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
OBSERVATIONAL
Inicio: 1 de may de 2012
ID: NCT01525199
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
INTERVENTIONAL
Inicio: 8 de oct de 2019
ID: NCT04026412
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations
INTERVENTIONAL
Inicio: 30 de sept de 2015
ID: NCT02546700
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
INTERVENTIONAL
Inicio: 30 de ene de 2023
ID: NCT05748600
Terminado
Fase 3
ClinicalTrials.gov
High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial
INTERVENTIONAL
Inicio: 21 de may de 2020
ID: NCT04395105
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
INTERVENTIONAL
Inicio: 28 de ago de 2024
ID: NCT06452277
Terminado
Fase 2
ClinicalTrials.gov
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.
INTERVENTIONAL
Inicio: 9 de sept de 2020
ID: NCT04410523
Reclutando
Fase 2
ClinicalTrials.gov
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
INTERVENTIONAL
Inicio: 1 de may de 2025
ID: NCT06929169
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
INTERVENTIONAL
Inicio: 2 de ene de 2026
ID: NCT07063745
Anterior
1
...
8
9
10
...
434
Siguiente
Filtros